SHTDY SINOPHARM GROUP CO
- 13.531
- +0.226+1.70%
SINOPHARM GROUP CO News
Sinopharm (01099.HK) received a shareholding of 1.7252 million shares of common stock from CITIC Securities Company Limited, worth approximately 35.6407 million Hong Kong dollars.
Reported on November 29th, according to the documents disclosed by the Hong Kong Stock Exchange on November 29th, CITIC Securities Company Limited increased its shareholding in sinopharm (01099.HK) by an average price of 20.6589 Hong Kong dollars per share on November 27th, with a total of 1.7252 million ordinary shares, worth approximately 35.6407 million Hong Kong dollars. After the increase, the latest number of shares held by CITIC Securities Company Limited is 81.69 million shares, and the warehouse-to-warehouse ratio has increased from 5.96% to 6.09%.
The new version of the medical insurance list adds 11 Chinese patent medicine varieties. Traditional Chinese medicine innovative drugs, classic famous prescriptions, and children's medications receive key support.
In 2024, the national medical insurance catalog was officially released today, with 91 pharmaceuticals newly added to the national medical insurance drug catalog, with an average price reduction of 63%; this time there are 11 new chinese patent medicines added, 10 of which are new drugs approved for marketing last year and this year.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
Sinopharm (01099.HK) received shareholding of 1.7252 million H shares from Citic Securities Asset Management Co., Ltd. and its affiliates, worth approximately 35.6407 million Hong Kong dollars.
On November 28, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on November 28, Citic Sec Asset Management Co., Ltd. increased its shareholding by purchasing 1.7252 million shares of Sinopharm (01099.HK) at an average price of HKD 20.6589 per share on November 27, valued at approximately HKD 35.6407 million. After the increase, Citic Sec Asset Management Co., Ltd. now holds a total of 80.5316 million shares, with the shareholding ratio rising from 5.87% to 6.00%. This trade involves other related parties: Citic Sec - Yunfan Single Asset Management Plan. Additional information: The equity belongs to Citic Sec.
Express News | Sinopharm and others established a new company in Liaoning, with a registered capital of 10 million.
The National Medical Insurance Administration: Negotiated pharmaceuticals during the agreement period have reduced the financial burden on patients by over 880 billion yuan.
This morning, the National Medical Insurance Administration announced the new version of the pharmaceutical catalog at a press conference. A responsible official from the National Medical Insurance Administration stated at the meeting that since its establishment, the speed of new drugs entering the catalog has continuously accelerated, allowing insured individuals to enjoy the benefits brought by pharmaceutical innovation in a timely manner. As of the end of October this year, the cumulative number of beneficiaries from negotiated pharmaceutical products during the agreement period reached 0.83 billion people, alleviating the financial burden on patients by more than 880 billion yuan. With more new drugs entering the catalog, the level of benefits for patients will steadily improve, which will effectively enhance the confidence of the pharmaceutical industry in increasing research and development innovation, conducive to better promoting economic and social development.
The new national medical insurance pharmaceutical list adds 91 types of pharmaceuticals, expecting to reduce the burden on patients by over 50 billion RMB next year.
The National Medical Insurance Bureau announced the new version of the pharmaceutical catalog at a press conference this morning. The criteria for the adjustment of this year's medical insurance catalog mainly include pharmaceuticals that have been newly launched or have modified descriptions in the past five years, medicines for rare diseases, children's drugs and generic drugs encouraged by the state for research and development, as well as essential drugs. Following the appropriate procedures, a total of 91 new pharmaceutical products have been added, including: 26 tumor drugs, 15 drugs for chronic diseases such as diabetes, 13 drugs for rare diseases, 7 anti-infection drugs, 11 chinese patent medicines, 4 psychiatric drugs, and 21 drugs from other fields. In this year's negotiation/bidding session, a total of 117 off-catalog pharmaceutical products participated.
Express News | 2024 Medical Insurance National Negotiation: 91 types of pharmaceuticals newly added to the list, with 89 types successfully negotiated outside the list.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Sinopharm (01099.HK) was reduced in shareholding by jpmorgan by 2.6938 million shares.
On November 27, Gelonghui reported that according to the latest equity disclosure information from the Hong Kong Stock Exchange, on November 21, 2024, sinopharm (01099.HK) had its shares reduced by JPMorgan Chase & Co. by 2.6938 million shares at an average price of HKD 20.6641 per share, involving approximately HKD 55.6641 million. After the shareholding, JPMorgan Chase & Co.'s latest number of held shares is 118,484,647, with the shareholding proportion decreasing from 9.03% to 8.83%.
Express News | The National Medical Insurance Administration will hold a press conference on Thursday this week to announce the adjustment of the national medical insurance pharmaceutical catalog for 2024, expecting to release the results of the medical insurance negoti
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics With Key Sinopharm(Hubei) Contracts
Sinopharm (01099.HK) has been increased by CITIC Securities Company Limited by 2.322 million ordinary shares, valued at approximately 49.2505 million Hong Kong dollars.
On November 25th, according to documents disclosed by the Hong Kong Stock Exchange on November 25th, CITIC Securities Company Limited increased its shareholding in Sinopharm (01099.HK) by an average price of HK$21.2104 per share on November 20th, acquiring 2.322 million ordinary shares, worth approximately HK$49.2505 million. Post the shareholding increase, CITIC Securities Company Limited's latest number of shares held is 69.1936 million shares, and the holding proportion increased from 4.98% to 5.16%.
62 pharmaceuticals have been included in the 10th batch of the national organized pharmaceutical procurement, with bidding starting on the 12th of next month.
According to CCTV, the National Medical Insurance Administration has learned that the National Drug Procurement Office has released a document that explicitly includes 62 types of pharmaceuticals in the scope of the tenth batch of national organized pharmaceutical central procurement. The declaration information will be opened for bidding in shanghai on December 12. Earlier, the previous nine batches of national organized pharmaceutical procurement involved a total of 374 types of pharmaceuticals, accounting for more than 30% of the procurement amount of public medical institutions, with an average reduction of over 50% in the procurement varieties.
"When will the 'medication' market return? Foreign capital and public offerings are racing to buy these pharmaceutical stocks.
The pharmaceutical industry has always been recognized as a "long slope and thick snow" track, and it is also one of the sectors that capital markets pay the most attention to.
Sinopharm Group Reports Nine-Month Financial Results
Sinopharm Group Reports Mixed Financial Results
Sinopharm (01099.HK) received shareholding of 2.322 million H shares from citic sec asset management co., ltd. and its affiliates, worth approximately 49.2505 million Hong Kong dollars.
On November 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on November 22, citic sec asset management limited increased its shareholding of $sinopharm (01099.HK) by 2.322 million shares listed in hong kong at an average price of 21.2104 HKD per share on November 20, worth approximately 49.2505 million HKD. After the shareholding increase, citic sec asset management limited's latest number of shares held is 68.0352 million shares, and the shareholding ratio rose from 4.90% to 5.07%. This trade involves other related parties: citic sec - Yun Fan single asset management plan. Additional information: The rights belong to citic sec.
Express News | Six institutions: improve the management of grassroots pharmaceuticals and expand the types of grassroots pharmaceuticals.
Analysis
Price Target
No Data
No Data